Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.

JAMA Netw Open · 2024 · PMC11036143 · PMID 38648061

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Using a Stockholm3 risk score cutoff of 0.11 or higher, a greater number of clinically significant prostate cancers was detected compared with the MRI-enhanced approach, although this difference did not reach statistical significance (relative proportion, 1.12; 95% CI, 0.90-1.38).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.